Novo Nordisk (0QIU) Gets a Sell From Jefferies
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Morgan Stanley Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $99
Berenberg Cuts Novo Nordisk's Price Target on Lower Wegovy Estimates
Novo Nordisk Target Cut to DKK460 From DKK880 by Intron Health
Novo Nordisk Stock Dips as Roche Licenses Rival Weight-Loss Drug
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
Morgan Stanley Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $99
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $159.5
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $105
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
CFRA Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $90
Argus Research Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $124
Novo Nordisk Analyst Ratings